Recent Updates
Recently added Catalysts

Durvalumab

Phase 2

Lung Cancer Stage II | Small molecule | Oncology |Atrium Therapeutics, Inc.|Last Updated: Feb 5, 2026

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLEDDMCBiomarker
Total Trials1
Total Enrollment61
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT03141359Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLCPHASE2 ACTIVE NOT_RECRUITING 61 — — May 12, 2017Jul 1, 2027Feb 5, 20261 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of Participants Progression Free and Surviving at 12 Months
From date of treatment start to date of progression or death, or censored at 12 months, whichever occurred first.

12-month progression free survival was determined for each subject as a binary variable indicating whether or not the subject was progression free and surviving at 12 months after study enrollment. Failure occurred if the subject progressed or died from any cause within 12 months of study enrollment. Disease progression was determined according to RECIST v1.1.

Secondary Endpoints
Progression Free Survival (PFS)
From date of treatment start to date of progression or death, or censored as described; assessed for approximately 5 years
Overall Survival (OS)
From date of treatment start to date of death, or censored as described; assessed for approximately 5 years
Radiologic Clinical Complete Response
Approximately 3 months after last treatment of concurrent mediastinal chemoradiation (on average, SBRT plus chemoradiation treatment lasted 2 months from baseline)
Unlock Study Endpoints
Study Design & Arms
AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Single ArmEXPERIMENTALSBRT + Concurrent Mediastinal Chemoradiation +/- Consolidation Chemotherapy/Adjuvant Immunotherapy
Interventions
NameTypeDescription
SBRTRADIATIONPrimary tumor SBRT
CarboplatinDRUGconcurrent chemotherapy
PaclitaxelDRUGconcurrent chemotherapy
cis PlatinumDRUGconcurrent chemotherapy
EtoposideDRUGconcurrent chemotherapy
IMRTRADIATIONmediastinal radiation
DurvalumabDRUGadjuvant immunotherapy
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria Subjects must meet all the following criteria: * Histologic or cytologic documentation of NSCLC (all histologies allowed) * Stage II or III disease (AJCC 7th Edition) based on imaging as required during screening: Stage II disease includes only subjects with medically inoperable...

Countries:United States
Unlock Eligibility Criteria
Recent Changes (Last 90 Days)
LOWMay 24, 2026NCT03141359studyFirstPostDate: changed